Mark Hebert, NP
Nurse Practitioner · Atlanta, GANPI 1831268630
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Viiv Healthcare Company accounts for 79.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $5,876 and has fallen 82.9% since, to $1,002 in 2025. Among nurse practitioner clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 343 payments — averaging $43.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$12K
- Gilead$1K
- Merck$566
- AbbVie$251
- Theratechnologies Inc.$243
- EMD Serono, Inc.$219
- plus $597 from 15 others
What the payments were for
- Consulting fees$7,57550%
- Travel & lodging$7345%
- Food & beverage$6,68645%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 184 | $11,890 |
| Gilead | 56 | $1,236 |
| Merck | 28 | $566 |
| AbbVie | 12 | $251 |
| Theratechnologies Inc. | 13 | $243 |
| EMD Serono, Inc. | 15 | $219 |
| Johnson & Johnson | 12 | $176 |
| Novo Nordisk | 5 | $95 |
| Verity Pharmaceuticals Inc. | 3 | $48 |
| Napo Pharmaceuticals Inc | 2 | $38 |
| Lilly USA, LLC | 2 | $37 |
| Exact Sciences | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Abbott | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Pfizer | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,001 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 341 | $1,336,298 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 113 | $474,006 |
| DovatoDolutegravir Sodium/Lamivudine | 128 | $365,724 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 74 | $335,799 |
| Egrifta SvTesamorelin Acetate | 25 | $233,399 |
| DescovyEmtricitabine/Tenofov Alafenam | 94 | $191,877 |
| PrezcobixDarunavir/Cobicistat | 74 | $173,537 |
| TivicayDolutegravir Sodium | 64 | $172,314 |
| CabenuvaCabotegravir/Rilpivirine | 26 | $160,230 |
| IsentressRaltegravir Potassium | 60 | $109,114 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 25 | $96,828 |
| Isentress HdRaltegravir Potassium | 47 | $88,897 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 24 | $81,488 |
| Etravirine | 38 | $40,071 |
| Darunavir | 33 | $33,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,236 | $2,002,181548 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Cabenuva, Triumeq | $11,890 | $795,095243 claims |
| Theratechnologies Inc.Egrifta Sv | $243 | $233,39925 claims |
| MerckIsentress, Isentress Hd | $566 | $198,011107 claims |
| Johnson & JohnsonPrezcobix | $176 | $173,53774 claims |
| PfizerEliquis | $16 | $13,55411 claims |
| GSKArexvy | $19 | $3,97415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Atlanta
- Janice McAlisterAtlanta$221K
- Laura ElledgeAtlanta$177K
- Casey MillerAtlanta$41K
- Kathryn InanAtlanta$17K
- Colby DoepelAtlanta$16K
- Ashley BlackmonAtlanta$13K
- Alexia CovingtonAtlanta$13K
- Marissa TorresAtlanta$12K
- Hayley TurnerAtlanta$11K
- Regena SpratlingAtlanta$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.